Lupus Nephritis
📧 Sign up to get email alerts when something new happens for Lupus Nephritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Phase IIa Study for IPG11406 in Patients With Lupus Nephritis [Phase 1, Phase 2]
A Phase 1/2 clinical trial update for IPG11406 in patients with lupus nephritis. The study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: BCMA-CD19 cCAR T for the Treatment of Refractory Lupus [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating BCMA-CD19 cCAR T therapy for refractory systemic lupus erythematosus and lupus nephritis, sponsored by…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases [Phase 1]
Century Therapeutics’ CNTY-101 is being evaluated in a Phase 1 study for refractory B cell–mediated autoimmune diseases, with the trial curr…
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: The Relation Between Serum Zinc and Lupus Nephritis
A new clinical trial is investigating the relationship between serum zinc levels and lupus nephritis, and it is currently not recruiting.
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old [Phase 1]
This document reports a Phase 1 clinical trial evaluating the safety and effects of Felzartamab in adults with lupus nephritis, sponsored by…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: VIBRANT: VIB4920 for Active Lupus Nephritis [Phase 2]
A Phase 2 trial evaluating VIB4920 for active lupus nephritis is currently recruiting, sponsored by the National Institute of Allergy and In…
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) [Phase 2]
A Phase 2 clinical trial evaluating the effectiveness and safety of efgartigimod in Chinese patients with lupus nephritis has been completed…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease [Phase 1]
A Phase 1 safety and efficacy study of CTX112 in adults with refractory autoimmune diseases, including systemic lupus erythematosus and syst…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus [Phase 1]
This Phase 1 clinical trial update shows AB-101, in combination with a B-cell depleting monoclonal antibody, is being studied in lupus nephr…
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis
A completed clinical trial evaluating the safety of Myfortic (mycophenolate sodium) in patients with lupus nephritis.
-
CLINICAL_TRIALS trial_result · 2025-12-05Clinical Trial Update: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) [Phase 2]
A Phase 2 study of Zetomipzomib (KZR-616) in patients with active lupus nephritis has been terminated, and results have been posted.
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis [Phase 2]
A Phase II clinical study evaluating the efficacy and safety of SHR-2173 injection for active lupus nephritis, with recruitment currently on…
-
EMA approval · 2025-11-24EMA Authorised: Lupkynis (voclosporin) — Otsuka Pharmaceutical Netherlands B.V.
The European Medicines Agency authorized Lupkynis (voclosporin) for the treatment of lupus nephritis, marking EU approval for this therapy.
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF [Phase 3]
Phase 3 trial update comparing induction therapy for lupus nephritis with oral corticosteroids plus mycophenolate mofetil (MMF) versus obinu…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Safety and Efficacy of ONT01 in Lupus [EARLY_Phase 1]
ONT01 is in an early Phase 1 trial for lupus nephritis and systemic lupus erythematosus and is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis [Phase 2]
Phase 2 trial evaluating HLX79 in combination with Rituximab versus placebo for active glomerulonephritis, including membranous nephropathy …
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis [Phase 3]
This update summarizes results from a Phase 3 study of obinutuzumab in ISN/RPS 2003 Class III or IV lupus nephritis. The trial status is act…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial [Phase 4]
A Phase 4 trial evaluating the safety and efficacy of combining belimumab with voclosporin for proliferative lupus nephritis; currently recr…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease [Phase 1]
Synthekine reports a Phase 1 study of SYNCAR-001 plus STK-009 without lymphodepletion in subjects with severe, refractory systemic autoimmun…
-
CLINICAL_TRIALS research · 2025-10-29Clinical Trial Update: KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis [Phase 1, Phase 2]
Clinical trial update for KYSA-3, an anti-CD19 CAR T-cell therapy, in subjects with refractory lupus nephritis (Phase 1/2; active/not recrui…
-
CLINICAL_TRIALS research · 2025-10-29Clinical Trial Update: KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis [Phase 1, Phase 2]
KYSA-1, an anti-CD19 CAR T-cell therapy, is being studied in refractory lupus nephritis in Phase 1/2 and is currently not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) [Phase 2]
Phase 2 study of ALXN2050 in proliferative lupus nephritis and IgA nephropathy was terminated, with results posted.
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases [Phase 1, Phase 2]
An open-label Phase 1/2 study evaluating povetacicept in autoantibody-associated glomerular diseases is active but not recruiting.
-
FDA approval · 2025-10-08FDA Approved: LUPKYNIS — Supplemental Application (Aurinia Pharma U.S., Inc.)
FDA approved a supplemental application for LUPKYNIS (voclosporin) submitted by Aurinia Pharma U.S., Inc. This page documents the regulatory…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. [EARLY_Phase 1]
Phase 1 study evaluating anti-CD19/BCMA universal CAR-T cell therapy RD06-05 in autoimmune diseases; the trial is currently recruiting.